| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2082491 | Drug Discovery Today: Technologies | 2013 | 6 Pages |
Abstract
Identifying the most effective new drugs for tuberculosis will depend on developing systems for preclinical testing that better reflect conditions in the diseased host and the characteristics of persistent M tuberculosis. Integrating information from these diverse new technologies using a model-based approach to anti-tuberculosis drug development could facilitate more effective use of this information in transitioning novel compounds successfully to the clinical phase.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
G.R. Davies,